20/20 Biolabs Inc.

AIDX

$0.61

-3.00%

N/A-$0.02

Healthcare

Medical - Care Facilities

NASDAQ

Active Trading

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer ...

Financial Highlights of AIDX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

31.5%

Net Margin

-285.0%

P/E Ratio

-0.80x

n/a

Debt / Equity

0.18

n/a

Current Ratio

1.99

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

31.5%

Net Margin

-285.0%

P/E Ratio

-0.80x

Debt / Equity

0.18

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	48.8%	46.3%	7.7%	20.6%	29.6%	—
Operating MarginOperating income as a percentage of revenue.	20.2%	15.2%	-446.6%	-323.1%	-162.9%	—
Net MarginNet income as a percentage of revenue.	21.5%	19.8%	-448.7%	-316.8%	-182.8%	—
EBITDA MarginEBITDA divided by revenue.	21.5%	17.8%	-434.9%	-315.3%	-171.4%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	21.5%	19.8%	-448.7%	-316.8%	-182.8%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	3.52	5.97	4.25	1.50	0.60	—
Quick RatioLiquid assets divided by current liabilities.	3.41	5.92	4.19	1.47	-46.59	—
Cash RatioCash and equivalents divided by current liabilities.	1.49	5.40	4.04	1.32	416.54	—
Debt / AssetsDebt as a share of total assets.	22.9%	19.8%	32.5%	41.9%	31035.0%	—
Debt / EquityDebt compared with shareholder equity.	0.34	0.26	0.48	0.99	-66789.49	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	2.28x	14.46x	20.69x	12.95x	0.01x	—
Inventory TurnoverHow often inventory is sold in a year.	19.98x	68.19x	21.68x	29.51x	0.01x	—
Payables TurnoverHow often payables are paid in a year.	5.91x	12.79x	3.65x	3.74x	0.00x	—
Asset TurnoverRevenue generated per dollar of assets.	0.94x	0.91x	0.22x	0.48x	0.49x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	2.33x	1.60x	0.25x	0.88x	-13.07x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	54.20x	51.85x	-17.80x	-20.56x	-39.75x	—
P/B RatioPrice paid for each dollar of book value.	16.37x	12.12x	26.53x	74.63x	-7761.78x	—
P/S RatioPrice paid for each dollar of sales.	11.72x	10.27x	79.85x	65.34x	72.96x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-86.62x	20.50x	-24.52x	-44.06x	-0.08x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Supply Chain of AIDX

RELATIONS

Upstream

Roche Diagnostics (F. Hoffmann-La Roche AG)SWX:ROIBM CorporationNYSE:IBM ROKIT Healthcare Inc.KOSDAQ:376900Roche Diagnostics GmbH (Manufacturing arm)SWX:ROChang Gung Memorial Hospital (CGMH)

Downstream

Evexia Diagnostics, Inc.State of Vermont (Department of Health)Chang Gung Memorial Hospital (CGMH)Functional & Integrative Medicine PractitionersDirect-to-Consumer (Company Website)

Proxies

Exact Sciences CorporationNASDAQ:EXAS Guardant Health, Inc.NASDAQ:GH GRAIL, Inc.NASDAQ:GRALRoche Holding AGSWX:ROHealwell AI Inc.TSX:AIDX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer